Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

Fleshner, Neil E; Lucia, M Scott; Egerdie, Blair; Aaron, Lorne; Eure, Gregg; Nandy, Indrani; Black, Libby; Rittmaster, Roger S

Fleshner, Neil E; Lucia, M Scott; Egerdie, Blair; Aaron, Lorne; Eure, Gregg; Nandy, Indrani; Black, Libby; Rittmaster, Roger S.

Affiliation

Fleshner NE; Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada. neil.fleshner@utoronto.ca

Lancet ; 379(9821): 1103-11, 2012 Mar 24.

Article in En | MEDLINE | ID: mdl-22277570

Subject(s)

5-alpha Reductase Inhibitors/therapeutic use; Azasteroids/therapeutic use; Prostatic Neoplasms/drug therapy; 5-alpha Reductase Inhibitors/administration & dosage; Aged; Aged, 80 and over; Anxiety/epidemiology; Azasteroids/administration & dosage; Disease Progression; Double-Blind Method; Dutasteride; Female; Humans; Male; Middle Aged; Proportional Hazards Models; Prostate-Specific Antigen/blood; Prostatic Neoplasms/pathology; Prostatic Neoplasms/psychology; Surveys and Questionnaires

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Azasteroids / 5-alpha Reductase Inhibitors Type of study: Clinical_trials / Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 2012 Type: Article Affiliation country: Canada

Fulltext

XML

PubMed Links

Search on Google